placebo

Vivus Adds 12% in Early Trading on Qnexa Study Results

blood pressure, clinical study, diet, drug, fat, health, lipid, medical, medication, obesity, pharma, pill, placebo, qnexa, trade, vivus, vvus, weight loss

Vivus (VVUS) is up by double digits in early trading, after it says long-term data demonstrated patients treated with the investigational drug QNEXA for two years showed reductions in blood pressure and the use of antihypertensive

By FNNO Staff
fnnonline@gmail.com

Repligen Reports Disappointing Bi-Polar Drug Results, Down Over 25%

The company noted that the 50 patients enrolled through academic medical centers did show a clinically meaningful improvement, while the 125 patients enrolled at the commercial clinical trial sites did not, and it would look in to

The stock is trading down 28% at $3.53 per share.

bipolar, clinical, disorder, drug, healthcare, medical, medicine, mental health, nasdaq, placebo, repligen, rgen, shares, stock, trial, uridine

Repligen Corporation (NASDAQ:RGEN) said Monday that a mid-stage clinical trial for its bi-polar drug RG2417, an oral form of uridine, did not significantly improve symptoms compared to a placebo over an eight-week period.

By Stephanie Shyu
sshyu@fnno.com

Vertex Pharmaceuticals Shares Up Over 14% On Positive Clinical Trial Results

The trial found patients taking the drug experienced a 17% relative improvement in their ability to force air out of their lungs in one second, a common measure of success in treating lung disease, compared with those on a placebo

Vertex's trial would have been deemed a success if it had delivered just a 4.5% improvement in the lung function test.

analyst, clinical, cystic fibrosis, disease, drugs, financial, health, healthcare, lungs, market, marketing, medical, medicine, nasdaq, patients, pharma, placebo, regulatory approval, shares, stock, trial, Vertex, vrtx, vx770

Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) are up over 14% today, after it announced positive clinical trial results for its cystic fibrosis fighting drug VX-770.

By Mathieu Lloyd
mlloyd@fnno.com

Teva Reports Positive Study Results for MS Treatment, Advanc

teva, pharmaceutical, active, biotech, acti, clinical, allegro, study, multiple, sclerosis, ms, patients, drug, laquinimod, placebo, relapse, remission, expanded, disability, severity, scale, edss, fnn

By Anonymous

Latest News from FNNO

XL Capital Looks to Continue to Trade Ab...

Shares of XL Capital (NYSE:XL) traded today at $35.52, breaking its 52-week high. So f ...

Skechers U.S.A. Makes a Move: Up 1.3%...

Skechers U.S.A. (NYSE:SKX) is one of today's biggest movers, up 1.3% to $54.10. The Do ...

Deckers Outdoor Shares Sinking Lower, Do...

Deckers Outdoor (NASDAQ:DECK) is one of today's biggest movers, down 1.3% to $89.57. T ...

Verizon Communications: The Winning Stre...

Verizon Communications (NYSE:VZ) traded at a new 52-week high today of $53.66. So far ...

Stock Investors Sell Off Shares of Shutt...

Shutterfly (NASDAQ:SFLY), a company whose shares are moving quickly, is trading 1.3% lo ...

Watch for Continued Gains in Shares of U...

Shares of Universal Health Services (NYSE:UHS) traded today at $110.43, breaking its 52 ...

Stock Investors Sell Off Shares of Lulul...

Lululemon Athletica (NASDAQ:LULU) is a company whose shares are active, trading 1.3% lo ...

Shares of UDR Have Risen Above Previous ...

Shares of UDR (NYSE:UDR) traded at a new 52-week high today of $29.36. This new high w ...

Most Popular Video News